Cargando…

Conventional fractionated helical tomotherapy for patients with small to medium hepatocellular carcinomas without portal vein tumor thrombosis

BACKGROUND: The purpose of this study was to evaluate clinical outcomes of conventional fractionated helical tomotherapy in patients with small to medium hepatocellular carcinomas (HCCs) without portal vein tumor thrombosis. METHODS: Patients with up to four HCC lesions not treatable by surgery or p...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Jinhong, Kong, Moonkyoo, Hong, Seong Eon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196793/
https://www.ncbi.nlm.nih.gov/pubmed/25328410
http://dx.doi.org/10.2147/OTT.S69618
_version_ 1782339530974560256
author Jung, Jinhong
Kong, Moonkyoo
Hong, Seong Eon
author_facet Jung, Jinhong
Kong, Moonkyoo
Hong, Seong Eon
author_sort Jung, Jinhong
collection PubMed
description BACKGROUND: The purpose of this study was to evaluate clinical outcomes of conventional fractionated helical tomotherapy in patients with small to medium hepatocellular carcinomas (HCCs) without portal vein tumor thrombosis. METHODS: Patients with up to four HCC lesions not treatable by surgery or percutaneous ablative therapies, <10 cm in the longest diameter, and no evidence of major vascular invasion were included. From January 2008 to January 2013, 20 patients with 33 tumors met the eligibility criteria and received definitive or salvage helical tomotherapy. The most commonly prescribed dose fractionation schedule was a total dose of 50 Gy with a daily dose of 2.5 Gy. Treatment response, survival, and radiation-induced toxicities were retrospectively reviewed. RESULTS: The median follow-up period after radiotherapy for all patients was 24.9 (range 7.8–79.2) months. Objective responses (complete response or partial response) occurred in 30 of 33 lesions (90.9%). Eight (24.2%) lesions showed local recurrence and the actuarial local control rate at 2 years was 69.5%. Intrahepatic recurrence-free survival and overall survival rates at 2 years were 45.7% and 71.1%, respectively. Age, Child–Pugh class, tumor response, local recurrence status, and intrahepatic recurrence status were significantly associated with overall survival on univariate analysis. Among these parameters, only local recurrence status showed marginal statistical significance on multivariate analysis (P=0.068). The overall survival rate at 2 years was 50% for patients who experienced local recurrence, but 87.5% for those who did not. No patient experienced grade 2 or greater general or gastrointestinal toxicity. There were no cases of radiation-induced liver disease. CONCLUSION: Conventional fractionated helical tomotherapy for patients with less than four small to medium HCCs without portal vein tumor thrombosis yielded favorable local control and overall survival without severe complications.
format Online
Article
Text
id pubmed-4196793
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-41967932014-10-17 Conventional fractionated helical tomotherapy for patients with small to medium hepatocellular carcinomas without portal vein tumor thrombosis Jung, Jinhong Kong, Moonkyoo Hong, Seong Eon Onco Targets Ther Original Research BACKGROUND: The purpose of this study was to evaluate clinical outcomes of conventional fractionated helical tomotherapy in patients with small to medium hepatocellular carcinomas (HCCs) without portal vein tumor thrombosis. METHODS: Patients with up to four HCC lesions not treatable by surgery or percutaneous ablative therapies, <10 cm in the longest diameter, and no evidence of major vascular invasion were included. From January 2008 to January 2013, 20 patients with 33 tumors met the eligibility criteria and received definitive or salvage helical tomotherapy. The most commonly prescribed dose fractionation schedule was a total dose of 50 Gy with a daily dose of 2.5 Gy. Treatment response, survival, and radiation-induced toxicities were retrospectively reviewed. RESULTS: The median follow-up period after radiotherapy for all patients was 24.9 (range 7.8–79.2) months. Objective responses (complete response or partial response) occurred in 30 of 33 lesions (90.9%). Eight (24.2%) lesions showed local recurrence and the actuarial local control rate at 2 years was 69.5%. Intrahepatic recurrence-free survival and overall survival rates at 2 years were 45.7% and 71.1%, respectively. Age, Child–Pugh class, tumor response, local recurrence status, and intrahepatic recurrence status were significantly associated with overall survival on univariate analysis. Among these parameters, only local recurrence status showed marginal statistical significance on multivariate analysis (P=0.068). The overall survival rate at 2 years was 50% for patients who experienced local recurrence, but 87.5% for those who did not. No patient experienced grade 2 or greater general or gastrointestinal toxicity. There were no cases of radiation-induced liver disease. CONCLUSION: Conventional fractionated helical tomotherapy for patients with less than four small to medium HCCs without portal vein tumor thrombosis yielded favorable local control and overall survival without severe complications. Dove Medical Press 2014-09-26 /pmc/articles/PMC4196793/ /pubmed/25328410 http://dx.doi.org/10.2147/OTT.S69618 Text en © 2014 Jung et al. This work is published by Dove Medical Press Ltd, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Ltd, provided the work is properly attributed.
spellingShingle Original Research
Jung, Jinhong
Kong, Moonkyoo
Hong, Seong Eon
Conventional fractionated helical tomotherapy for patients with small to medium hepatocellular carcinomas without portal vein tumor thrombosis
title Conventional fractionated helical tomotherapy for patients with small to medium hepatocellular carcinomas without portal vein tumor thrombosis
title_full Conventional fractionated helical tomotherapy for patients with small to medium hepatocellular carcinomas without portal vein tumor thrombosis
title_fullStr Conventional fractionated helical tomotherapy for patients with small to medium hepatocellular carcinomas without portal vein tumor thrombosis
title_full_unstemmed Conventional fractionated helical tomotherapy for patients with small to medium hepatocellular carcinomas without portal vein tumor thrombosis
title_short Conventional fractionated helical tomotherapy for patients with small to medium hepatocellular carcinomas without portal vein tumor thrombosis
title_sort conventional fractionated helical tomotherapy for patients with small to medium hepatocellular carcinomas without portal vein tumor thrombosis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196793/
https://www.ncbi.nlm.nih.gov/pubmed/25328410
http://dx.doi.org/10.2147/OTT.S69618
work_keys_str_mv AT jungjinhong conventionalfractionatedhelicaltomotherapyforpatientswithsmalltomediumhepatocellularcarcinomaswithoutportalveintumorthrombosis
AT kongmoonkyoo conventionalfractionatedhelicaltomotherapyforpatientswithsmalltomediumhepatocellularcarcinomaswithoutportalveintumorthrombosis
AT hongseongeon conventionalfractionatedhelicaltomotherapyforpatientswithsmalltomediumhepatocellularcarcinomaswithoutportalveintumorthrombosis